Organogenesis Holdings earnings release, August 6, 2026

Organogenesis Holdings Inc. (ORGO) · Form 8-K, Item 2.02 · Filed · SEC filing

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results

CANTON, Mass.,

(August 6, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Financial Results Summary:

• Net revenue of $42.8 million for the second quarter of 2026, a decrease of $58.0 million compared to net revenue of $100.8 million for the second quarter of 2025. Net revenue for the second quarter of 2026 consists of: o

Net revenue from Advanced Wound Care products of $36.1 million, a decrease of 61% from the second quarter of 2025. o

Net revenue from Surgical & Sports Medicine products of $6.7 million, a decrease of 18% from the second quarter of 2025.

• Net loss of $96.3 million for the second quarter of 2026, compared to a net loss of $9.4 million for the second quarter of 2025, an increase in net loss of $86.9 million.

• Adjusted net loss of $89.0 million for the second quarter of 2026, compared to an adjusted net loss of $7.5 million for the second quarter of 2025, an increase in adjusted net loss of $81.5 million.

• Adjusted EBITDA loss of $34.4 million for the second quarter of 2026, compared to Adjusted EBITDA loss of $3.6 million for the second quarter of 2025, an increase in EBITDA loss of $30.7 million.

"We are encouraged by signs of measured improvement in business trends in the second quarter, though the pace of recovery from the significant market contraction is slower than we expected," said Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis. "Our business is built on efficacy and outcomes, and that is driving our expanding share as the market resets and customers turn to solutions they can trust. We remain convinced that we occupy the strongest long-term position and will remain the leader with the best evidence-based regenerative medicine products, while advancing the ReNu program to unlock new markets for the company."

Second Quarter 2026 Financial Results:

Net product revenue for the second quarter of 2026 was $42.8 million, compared to $100.8 million for the second quarter of 2025, a decrease of $58.0 million, or 58%. The decrease in net product revenue was driven by a decrease of $56.6 million, or 61%, in net product revenue for Advanced Wound Care products.

Gross profit for the second quarter of 2026 was $19.1 million, or 45% of net product revenue, compared to $73.1 million, or 73% of net product revenue for the second quarter of 2025, a decrease of $54.0 million, or 74%.

Operating expenses for the second quarter of 2026 were $94.7 million compared to $113.6 million for the second quarter of 2025, a decrease of $18.8 million, or 17%. Cost of goods sold was $23.7 million for the second quarter of 2026, compared to $27.6 million for the second quarter of 2025, a decrease of $4.0 million, or 14%.

Selling, general and administrative expenses were $54.0 million for the second quarter of 2026, compared to $73.8 million for the second quarter of 2025, a decrease of $19.8 million, or 27%. R&D expense was $18.3 million for the second quarter of 2026, compared to $10.4 million for the second quarter of 2025, an increase of $7.9 million, or 76%.

Operating loss for the second quarter of 2026 was $51.0 million, compared to an operating loss of $12.6 million for the second quarter of 2025, an increase in operating loss of $38.4 million.

Total other income, net, for the second quarter of 2026 was $0.1 million, compared to $0.7 million for the second quarter of 2025, a decrease of $0.6 million.

Net loss for the second quarter of 2026 was $96.3 million, or $(0.77) per share, compared to net loss of $9.4 million, or $(0.10) per share, for the second quarter of 2025, an increase in net loss of $86.9 million, or $(0.67) per share.

Adjusted net loss was $89.0 million for the second quarter of 2026, compared to adjusted net loss of $7.5 million for the second quarter of 2025, an increase in adjusted net loss of $81.5 million.

Adjusted EBITDA loss was $34.4 million for the second quarter of 2026, compared to Adjusted EBITDA loss of $3.6 million for the second quarter of 2025, an increase in adjusted EBITDA loss of $30.7 million.

Non-GAAP operating loss was $41.1 million for the second quarter of 2026, compared to non-GAAP operating loss of $10.0 million for the second quarter of 2025, an increase in non-GAAP operating loss of $31.1 million.

Six Months ended June 30,2026 Financial Results:

Net product revenue for the six months ended June 30, 2026 was $79.1 million, compared to $187.5 million for the six months ended June 30, 2025, a decrease of $108.4 million, or 58%. The decrease in net product revenue was driven by a decrease of $107.0 million, or 62%, in net product revenue for Advanced Wound Care products.

Gross profit for the six months ended June 30, 2026 was $29.6 million, or 37% of net product revenue, compared to $136.1 million, or 73% of net product revenue for the six months ended June 30, 2025, a decrease of $106.5 million, or 78%.

Operating expenses for the six months ended June 30, 2026 were $200.9 million compared to $227.0 million for the six months ended June 30, 2025, a decrease of $26.2 million, or 12%. Cost of goods sold was $49.4 million for the six months ended June 30, 2026, compared to $51.4 million for the six months ended June 30, 2025, a decrease of $1.9 million, or 4%.... (truncated)7.2 million, or 19%. R&D expense was $33.5 million for the six months ended June 30, 2026, compared to $21.0 million for the six months ended June 30, 2025, an increase of $12.4 million, or 59%.

Operating loss for the six months ended June 30, 2026 was $119.9 million, compared to an operating loss of $39.3 million for the six months ended June 30, 2025, an increase in operating loss of $80.6 million.

Total other income, net, for the six months ended June 30, 2026 was $0.5 million, compared to $1.7 million for the six months ended June 30, 2025, a decrease of $1.2 million.

Net loss for the six months ended June 30,2026 was $149.4 million, or $(1.21) per share, compared to net loss of $28.2 million, or $(0.27) per share, for the six months ended June 30, 2025, an increase in net loss of $121.2 million, or $(0.94) per share.

Adjusted net loss was $132.8 million for the six months ended June 30, 2026, compared to adjusted net loss of $20.9 million for the six months ended June 30, 2025, an increase in adjusted net loss of $111.8 million.

Adjusted EBITDA loss was $82.5 million for the six months ended June 30, 2026, compared to Adjusted EBITDA loss of $16.2 million for the six months ended June 30, 2025, an increase in adjusted EBITDA loss of $66.4 million.

Non-GAAP operating loss was $97.1 million for the six months ended June 30, 2026, compared to non-GAAP operating loss of $29.3 million for the six months ended June 30, 2025, an increase in non-GAAP operating loss of $67.7 million.

As of June 30, 2026, the Company had $46.8 million in cash, cash equivalents and restricted cash and no outstanding debt obligations, compared to $94.3 million in cash, cash equivalents and restricted cash and no outstanding debt obligations as of December 31, 2025.

Fiscal Year 2026 Outlook:

For the year ending December 31, 2026, the Company now expects:

• Total net revenue between $179.0 million and $215.0 million, representing a decline in the range of 62% to 68%, as compared to total net revenue of $564.2 million for the year ended December 31, 2025. o

Our updated total revenue guidance continues to reflect the expectation that we see sequential improvement in our revenue trends in the in the third and fourth quarters, however, at a more measured rate versus what our prior guidance assumed, resulting in a second half revenue decline in the range of approximately 64% to 74% year over year, and compared to our prior guidance range which assumed a decline in the range of 45% to 52% year-over-year.

Second Quarter Earnings Conference Call:

Management will host a conference call at 5:00 p.m. Eastern Time on August 6th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.

ORGANOGENESIS HOLDINGS INC.

UNAUDITED CONDENSED CONSOLIDATED BA

LANCE SHEETS

(amounts in thousands, except share and per share data)

Financial statements

Income Statement

Three Months Ended June 30, — (amounts in thousands, except share and per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue:Net product revenue42,805100,77979,055187,472
Revenue:Grant income9502261,928226
Revenue:Total revenue43,755101,00580,983187,698
Operating expenses:Cost of goods sold23,67327,63049,44551,353
Operating expenses:Selling, general and administrative53,96573,810119,151146,319
Operating expenses:Research and development18,29710,39533,45821,035
Operating expenses:Fair value adjustment to assets held for sale-1,1881,746-1,1888,313
Operating expenses:Total operating expenses94,747113,581200,866227,020
Operating expenses:Loss from operations-50,992-12,576-119,883-39,322
Other income, net:Interest income, net1386695181,630
Other income, net:Other income (expense), net-26731275
Other income, net:Total other income, net1127425301,705
Other income, net:Net loss before income taxes-50,880-11,834-119,353-37,617
Other income, net:Income tax benefit (expense)-45,3872,442-30,0709,382
Other income, net:Net loss and comprehensive loss-96,267-9,392-149,423-28,235
Other income, net:Accretion of redeemable convertible preferred stock to redemption value-170-129-329-250
Other income, net:Cumulative dividend on redeemable convertible preferred stock-2,902-2,681-5,746-5,308
Other income, net:Net loss attributable to common stockholders-99,339-12,202-155,498-33,793
Net loss per share:Basic and diluted-0.77-0.1-1.21-0.27
Weighted-average common shares outstanding:Basic and diluted128,674,548126,853,536128,238,204126,576,130

Income Statement

Three Months Ended June 30, — The following table presents a reconciliation of GAAP net loss to non-GAAP EBITDA and non-GAAP Adjusted EBITDA, for the periods presented: (in thousands)

Three Months Ended June 30, – 2026 – (Unaudited, in thousands)Three Months Ended June 30, – 2025 – (Unaudited, in thousands)Six Months Ended June 30, – 2026 – (Unaudited, in thousands)Six Months Ended June 30, – 2025 – (Unaudited, in thousands)
Net loss-96,267-9,392-149,423-28,235
Interest income, net-138-669-518-1,630
Income tax (benefit) expense45,387-2,44230,070-9,382
Depreciation and amortization3,6683,7347,8427,178
Amortization of intangible assets (1)4338416,1411,683
EBITDA-46,917-7,928-105,888-30,386
Stock-based compensation expense3,0522,5426,6885,909
Inventory write-downs (2)3,327
Restructuring charge (3)5,0998,957
Fair value adjustment to assets held for sale (4)-1,1881,746-1,1888,313
R&D program termination costs (5)5,5885,588
Adjusted EBITDA-34,366-3,640-82,516-16,164

Income Statement

Three Months Ended June 30, — The following table presents a reconciliation of GAAP net loss from operations to non-GAAP operating loss, for the periods presented: (in thousands)

Three Months Ended June 30, – 2026 – (Unaudited, in thousands)Three Months Ended June 30, – 2025 – (Unaudited, in thousands)Six Months Ended June 30, – 2026 – (Unaudited, in thousands)Six Months Ended June 30, – 2025 – (Unaudited, in thousands)
Loss from operations-50,992-12,576-119,883-39,322
Amortization of intangible assets (1)4338416,1411,683
Inventory write-downs (2)3,327
Restructuring charge (3)5,0998,957
Fair value adjustment to assets held for sale (4)-1,1881,746-1,1888,313
R&D program termination costs (5)5,5885,588
Non-GAAP operating loss-41,060-9,989-97,058-29,326

Balance Sheet

December 31, — (amounts in thousands, except share and per share data)

June 30, – 2026December 31, – 2025
Current assets:Cash and cash equivalents46,09793,679
Current assets:Restricted cash747652
Current assets:Accounts receivable, net100,937217,451
Current assets:Inventories, net29,28029,627
Current assets:Asset held for sale3,6132,425
Current assets:Prepaid expenses and other current assets19,62818,354
Current assets:Total current assets200,302362,188
Current assets:Property and equipment, net101,531103,711
Current assets:Intangible assets, net3,0049,145
Current assets:Goodwill28,77228,772
Current assets:Operating lease right-of-use assets, net49,91255,749
Current assets:Deferred tax asset, net29,962
Current assets:Other assets22,9259,203
Current assets:Total assets406,446598,730
Current liabilities:Current portion of finance lease obligations8599,435
Current liabilities:Current portion of operating lease obligations - related party4,6474,258
Current liabilities:Current portion of operating lease obligations3,8074,949
Current liabilities:Accounts payable29,29131,949
Current liabilities:Accrued expenses and other current liabilities18,35949,533
Current liabilities:Total current liabilities56,963100,124
Current liabilities:Finance lease obligations, net of current portion10,82012,788
Current liabilities:Operating lease obligations, net of current portion - related party25,73828,237
Current liabilities:Operating lease obligations, net of current portion21,07922,470
Current liabilities:Other liabilities3,7141,193
Current liabilities:Total liabilities118,314164,812

Cash Flow

Six Months Ended June 30, — (amounts in thousands, except share and per share data)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cash flows from operating activities:Net loss-149,423-28,235
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization7,8427,178
Adjustments to reconcile net loss to net cash used in operating activities:Amortization of intangible assets6,1411,683
Adjustments to reconcile net loss to net cash used in operating activities:Reduction in the carrying value of right-of-use assets4,9744,077
Adjustments to reconcile net loss to net cash used in operating activities:Non-cash interest expense181139
Adjustments to reconcile net loss to net cash used in operating activities:Deferred tax expense (benefit)29,962-2,292
Adjustments to reconcile net loss to net cash used in operating activities:Provision recorded for credit losses-2,9753,116
Adjustments to reconcile net loss to net cash used in operating activities:Loss on disposal of property and equipment39544
Adjustments to reconcile net loss to net cash used in operating activities:Adjustment for excess and obsolete inventories8,2596,093
Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation6,6885,909
Adjustments to reconcile net loss to net cash used in operating activities:Fair value adjustment to assets held for sale-1,1888,313
Changes in operating assets and liabilities:Accounts receivable119,489-13,637
Changes in operating assets and liabilities:Inventories-11,812-15,892
Changes in operating assets and liabilities:Prepaid expenses and other current assets and other assets4,810-12,942
Changes in operating assets and liabilities:Operating leases-3,780-4,147
Changes in operating assets and liabilities:Accounts payable-1,3981,637
Changes in operating assets and liabilities:Accrued expenses and other current liabilities-29,281-13,886
Changes in operating assets and liabilities:Other liabilities59034
Changes in operating assets and liabilities:Net cash used in operating activities-10,526-52,808
Cash flows from investing activities:Purchases of property and equipment-4,246-7,264
Cash flows from investing activities:Net cash used in investing activities-4,246-7,264
Cash flows from financing activities:Payments of withholding taxes in connection with RSUs vesting-3,051-1,796
Cash flows from financing activities:Proceeds from the exercise of stock options25
Cash flows from financing activities:Principal repayments of finance lease obligations-10,188-573
Cash flows from financing activities:Construction of landlord assets, net of tenant allowance-19,476
Cash flows from financing activities:Net cash used in financing activities-32,715-2,344
Cash flows from financing activities:Change in cash, cash equivalents and restricted cash-47,487-62,416
Cash flows from financing activities:Cash, cash equivalents, and restricted cash, beginning of period94,331136,151
Cash flows from financing activities:Cash, cash equivalents, and restricted cash, end of period46,84473,735
Supplemental disclosure of non-cash investing and financing activities:Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock6,0755,558
Supplemental disclosure of non-cash investing and financing activities:Change in purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities-379-38
Supplemental disclosure of non-cash investing and financing activities:Landlord asset additions included in accounts payable and accrued expenses and other current liabilities, net of tenant allowances3,704$—
Supplemental disclosure of non-cash investing and financing activities:Right-of-use assets obtained through finance lease obligations-357$—
Supplemental disclosure of non-cash investing and financing activities:Right-of-use assets obtained through operating lease obligations$—1,815

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Organogenesis Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.